Arvinas (ARVN) Stock Price, News & Analysis

Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Key Stats

• Today's Range: $8.43 to $9.55
• 50-Day Range: $8.30 to $20.50
• 52-Week Range: $7.91 to $46.23
• Volume: 5.42 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: $588.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.47
• Consensus Rating: Moderate Buy

Arvinas Stock Analysis - MarketRank™

Arvinas scored higher than 58% of companies evaluated by MarketBeat, and ranked 457th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arvinas has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arvinas is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arvinas is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arvinas has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.49% of the float of Arvinas has been sold short.

Short Interest Ratio / Days to Cover

Arvinas has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Arvinas has recently increased by 10.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arvinas does not currently pay a dividend.

Dividend Growth

Arvinas does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.49% of the float of Arvinas has been sold short.

Short Interest Ratio / Days to Cover

Arvinas has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Arvinas has recently increased by 10.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: -0.14

News Sentiment

Arvinas has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 38 news articles for Arvinas this week, compared to 6 articles on an average week.

Search Interest

22 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

MarketBeat Follows

19 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 375% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $695,030.00 in company stock.

Percentage Held by Insiders

Only 5.23% of the stock of Arvinas is held by insiders.

Percentage Held by Institutions

95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARVN Stock Analysis - Frequently Asked Questions

How have ARVN shares performed this year?

Arvinas' stock was trading at $19.17 on January 1st, 2025. Since then, ARVN stock has decreased by 55.4% and is now trading at $8.55.
View the best growth stocks for 2025 here.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Tuesday, February, 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative trailing twelve-month return on equity of 33.75% and a negative net margin of 75.51%.

When did Arvinas IPO?

Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' top institutional investors include Vanguard Group Inc. (10.28%), Price T Rowe Associates Inc. MD (5.97%), RTW Investments LP (4.85%) and Bellevue Group AG (3.48%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Ronald Peck, Briggs Morrison and David K Loomis.
View institutional ownership trends.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 2/11/2025
• Today: 3/13/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARVN
• CIK: 1655759
• Web: www.arvinas.com
• Phone: (203) 535-1456
• Fax: N/A
• Employees: 420
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $41.07
• High Stock Price Target: $81.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +362.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-198,900,000.00
• Net Margins: -75.51%
• Pretax Margin: -75.29%
• Return on Equity: -33.75%
• Return on Assets: -16.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.64
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: $263.40 million
• Price / Sales: 2.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.17 per share
• Price / Book: 1.09

Miscellaneous

• Outstanding Shares: 68,772,000
• Free Float: 65,175,000
• Market Cap: $611.04 million
• Optionable: Optionable
• Beta: 1.95